StockNote
DPH
Hai Phong Pharmaceutical Joint Stock Company (DPH), formerly known as Hai Phong National Pharmaceutical Joint Stock Company, was established in 1961. The Company's main production activities are the production and trading of pharmaceuticals and medicinal materials. DPH has officially operated under the model of a joint stock company since 2006. The company is operating a GMP-WHO factory, including 3 GMP-standard eye drops, nasal tablets and soft capsules lines, a GLP-standard laboratory and a warehouse system close to a warehouse system of nearly 1,000m2 meeting GSP standards. DPH has been traded on the UPCOM market since January 2017.
DPH currently has a market capitalization of roughly VND 141 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 3,6x is 32% below its own 6-year average (5,2x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 0,6x, 6% below its multi-year average of 0,6x. Return on equity (ROE) is at 10,7%. Its debt-to-equity ratio of 0x is low, reflecting a conservative capital structure. In 2025, revenue fell 1% year-on-year while after-tax profit grew 6%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Revenue & Profit
Unit: VND billion. Growth (%) vs. previous period.
Market Cap
Unit: VND billion. Year-end values; current year uses latest session.
Debt / Equity
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.